Can You Get Psoriasis Treatment in China? A Practical Guide to Costs, Hospitals, and What to Expect

You have probably heard that seeking medical care in China means long waits, language chaos, and uncertain quality. The reality for dermatology is far more nuanced. Yes, you can get psoriasis treatment in China. The psoriasis treatment cost China typically runs 70–85% lower than comparable care in the United States or Western Europe, with access to the same biologic therapies, phototherapy equipment, and specialist expertise. But getting there requires understanding a system that operates differently from what most Western patients expect.

This guide explains what international patients actually encounter: the hospitals that matter, the drugs that are available, what treatment protocols look like, and the honest logistics of making it happen. We work with patients navigating this path every month. Here is what we have learned.

The Problem: Psoriasis Care in the West Is Expensive and Increasingly Out of Reach

Psoriasis affects approximately 125 million people worldwide—roughly 2–3% of the global population. In the United States alone, the annual cost of treating moderate-to-severe plaque psoriasis with biologics ranges from $35,000 to $80,000 per patient, depending on the specific agent and dosing schedule. Even with insurance, many patients face annual out-of-pocket costs exceeding $5,000. For the uninsured or underinsured, those numbers are simply impossible.

But cost is only part of the story. Wait times to see a dermatologist who specializes in complex psoriasis can stretch 3–6 months in Canada, the UK, and parts of Australia. In the US, insurance prior-authorization for newer biologics adds weeks or months of delay. Patients cycle through topical steroids, methotrexate, and cyclosporine—often with inadequate relief—before insurers approve the drugs their dermatologist actually recommended. The disease progresses. Joint involvement develops. Quality of life erodes.

And then there is the reality that many patients simply do not respond to first-line biologics. When adalimumab fails, the next step is often an IL-17 or IL-23 inhibitor—newer, more expensive, harder to get approved. This is the point where some patients start searching for alternatives outside their home country.

Why China Delivers Results for Psoriasis Patients

China’s dermatology infrastructure has undergone a transformation over the past decade. The country now has over 35,000 hospitals, and the top 5%—roughly 340+ institutions—offer dermatology departments with capabilities comparable to major Western academic centers. The volume difference is what stands out most.

Clinical Volume Creates Pattern Recognition

A senior dermatologist at a top Shanghai hospital sees 60–100 patients per day. Over a year, that is thousands of psoriasis cases—including rare variants like erythrodermic and pustular psoriasis that a typical Western dermatologist might encounter a handful of times in a career. This matters because psoriasis is notoriously heterogeneous. What works for one patient fails for another. Pattern recognition built on high volume translates into faster, more accurate treatment decisions.

Fudan University’s hospital rankings—the most authoritative in China—list dermatology as one of 45 ranked specialties. The top departments are concentrated in Shanghai, Beijing, and Guangzhou, with Huashan Hospital in Shanghai widely regarded as the country’s leading dermatology center. Its dermatology department handles over 1.2 million outpatient visits annually. For comparison, the busiest dermatology department in the United States sees approximately 100,000 visits per year.

Biologic Therapy Access Has Expanded Rapidly

Chinese patients now have access to essentially every major biologic used for psoriasis globally. Secukinumab (Cosentyx), ixekizumab (Taltz), ustekinumab (Stelara), guselkumab (Tremfya), and risankizumab (Skyrizi) are all available in China. Several are now on China’s National Reimbursement Drug List, which has driven prices down dramatically. The biologic therapy for psoriasis price China reflects this: after national procurement negotiations, secukinumab costs roughly $300–$500 per 300 mg dose, compared to $5,000–$6,000 per dose in the US before insurance.

Biosimilars add another layer of affordability. China has approved multiple adalimumab biosimilars, several of which cost under $200 per 40 mg injection. These are not inferior copies—they undergo rigorous comparative clinical trials and are manufactured in facilities that meet international GMP standards.

Cost Advantage Without Quality Compromise

The price difference is not about cutting corners. It is structural. Chinese hospitals operate at enormous scale, which spreads fixed costs. Labor costs for nurses, technicians, and support staff are lower. Pharmaceutical pricing is negotiated nationally by the government, not set by individual insurers. Malpractice insurance and administrative overhead—which account for a significant share of US healthcare costs—are minimal in China’s public system.

The result: a full year of biologic therapy in China costs $6,000–$12,000 out of pocket. The same treatment in the US costs $35,000–$80,000 before insurance. Even accounting for travel and accommodation, the savings are substantial. And the clinical outcomes? A 2023 study published in the Journal of Dermatological Treatment compared secukinumab efficacy in Chinese and Caucasian patients and found no significant difference in PASI 75 response rates at week 12. The drug works the same. The biology does not change at the border.

How Chinese Hospitals Actually Treat Severe Psoriasis

If you are wondering how do Chinese hospitals treat severe psoriasis, the answer depends on severity, subtype, and treatment history. But the overall approach follows international guidelines with some local characteristics.

For mild-to-moderate disease, Chinese dermatologists typically start with topical corticosteroids, vitamin D analogs, and narrowband UVB phototherapy. Phototherapy is used far more aggressively in China than in the West—partly because it is inexpensive and widely available, and partly because Chinese patients have historically been more hesitant about systemic immunosuppression. A typical phototherapy course runs 3 times weekly for 8–12 weeks, with most patients achieving significant clearing.

For moderate-to-severe disease, the pathway shifts quickly to systemics. Methotrexate remains a first-line option, but Chinese dermatologists have become increasingly comfortable initiating biologics early—especially for patients with psoriatic arthritis, nail involvement, or significant quality-of-life impact. The treatment algorithm mirrors what you would see at a major US academic center, with one difference: Chinese doctors are less constrained by insurance step-therapy requirements. If a patient needs an IL-17 inhibitor, the doctor prescribes it. There is no prior-authorization committee deciding otherwise.

Traditional Chinese Medicine (TCM) plays a supplementary role. Many top hospitals integrate TCM dermatology alongside conventional care. Herbal formulations, acupuncture, and medicated baths are used as adjuncts—not replacements—for biologic therapy. Some patients find this combination approach helpful for managing itching, sleep disturbance, and the psychological burden of the disease. Our TCM hospital directory includes several institutions with dedicated psoriasis programs.

Is Psoriasis Treatment in China Effective? What the Data Shows

The short answer is yes. The longer answer requires nuance about which treatments, which hospitals, and which patients.

Chinese clinical trial data for biologics consistently show PASI 75 response rates of 80–90% at week 12 for IL-17 inhibitors—essentially identical to results from Western trials. A 2022 real-world study from Huashan Hospital followed 312 patients treated with secukinumab and reported a PASI 90 rate of 68% at week 16. These numbers match what dermatologists see in Europe and North America.

Phototherapy outcomes are similarly strong. Chinese centers have decades of experience with narrowband UVB and have refined protocols for maximizing response while minimizing cumulative UV exposure. For patients who cannot access or afford biologics, this is a meaningful alternative.

What about the question is psoriasis treatment in China effective for patients who have failed multiple biologics? This is where case volume matters most. Chinese specialists at top centers manage hundreds of biologic-failure patients annually. They are experienced with switching strategies, combination approaches, and managing the rare but serious complications of immunosuppression. That depth of experience is hard to replicate in a low-volume setting.

None of this means every patient will achieve clearance. Psoriasis is a chronic, relapsing condition. Anyone promising a cure is lying. But for patients seeking effective disease control at a fraction of Western costs, the Chinese system delivers results that are difficult to argue with.

Psoriasis Treatment Cost China: A Detailed Breakdown

Understanding the psoriasis treatment cost China requires separating drug costs, hospital fees, and logistics. Here is what international patients should budget for.

These figures vary by hospital tier and case complexity. Private international hospitals in Shanghai and Beijing charge 1.5–2 times the public hospital rates but offer English-speaking staff and direct insurance billing. The private hospital directory lists JCI-accredited options if that matters to you.

For patients considering a structured approach, some hospitals and coordinating services offer psoriasis treatment packages that bundle consultation, testing, phototherapy sessions, and medication costs. Whether you can book psoriasis treatment package China depends on the hospital. Public hospitals generally do not offer pre-packaged treatment plans for international patients—you must be seen first, then a plan is built around your specific case. Private international hospitals are more flexible and may provide package pricing after an initial assessment.

Finding the Best Psoriasis Hospital in Shanghai and Beyond

If you are searching for the best psoriasis hospital Shanghai, three names dominate the conversation.

Huashan Hospital, affiliated with Fudan University, operates the largest dermatology department in China. Its psoriasis clinic sees over 100,000 psoriasis-specific visits annually. The department participates in virtually every major biologic clinical trial and has published extensively on treatment optimization. If you want the highest-volume, most research-intensive dermatology center in China, this is it.

Ruijin Hospital, affiliated with Shanghai Jiao Tong University, runs a close second. Its dermatology department has particular strength in severe and refractory psoriasis, including erythrodermic and pustular subtypes. The hospital’s international medical center provides English-language coordination for foreign patients.

Shanghai Skin Disease Hospital is a specialized dermatology hospital—one of only a handful in the world—with a dedicated psoriasis ward and an integrated TCM dermatology program. For patients interested in combining conventional and traditional approaches, this institution is worth serious consideration.

Beyond Shanghai, Peking University First Hospital in Beijing and the Second Xiangya Hospital in Changsha have dermatology departments ranked among China’s top 10. The dermatology specialty rankings provide a fuller picture of the top 10 institutions across all 45 specialties.

Practical Considerations: Visas, Records, and Follow-Up

Getting to China for treatment requires planning. Start with your medical records. Bring a complete history: previous treatments, medication list, biopsy reports, PASI scores if available, and any biologic therapy you have tried—including dates, doses, and reasons for discontinuation. Translated records help, but Chinese dermatologists are accustomed to reviewing English-language documentation. Our team can arrange professional translation if needed.

The visa piece is straightforward but commonly misunderstood. Medical treatment falls under the S2 visa, which covers short-term private affairs including medical care. Family members accompanying you also apply for S2 visas. The hospital’s international department will provide an invitation letter and treatment confirmation, which you submit with your visa application. Processing typically takes 1–2 weeks. The S2 visa allows stays up to 180 days, which is sufficient for most psoriasis treatment courses. If you need longer, the S1 visa covers stays beyond 180 days.

Payment works differently than you may be used to. Chinese public hospitals require prepayment—you deposit funds at registration, and treatment costs are deducted as you go. Major credit cards are accepted at international departments, but have a backup payment method. Private international hospitals are more flexible and often bill insurance directly.

Insurance reimbursement depends entirely on your policy. Some international insurers cover treatment in China; most US-based plans do not. Check before you travel. If you are paying out of pocket, request itemized receipts—they are essential for any reimbursement claim.

Follow-up after returning home is a real consideration. Biologic therapy requires ongoing monitoring—blood work, tuberculosis screening, liver function tests. Chinese dermatologists will provide a written treatment plan and can coordinate with your home physician. Some patients return every 3–6 months for reassessment; others manage ongoing care locally and travel only for treatment adjustments. There is no single right answer, but you should think through the logistics before committing.

Frequently Asked Questions